Lymphadenopathy — Swelling of the Lymph Nodes

Lymphadenopathy describes lymph nodes that have expanded beyond normal physiological dimensions, generally defined as exceeding one centimetre in diameter, though thresholds vary by anatomical location. The swelling occurs when an influx of immune cells gathers to combat an antigen or when abnormal cells multiply internally within the nodal capsule.

In oncological contexts, this presentation arises from primary lymphoid malignancies, such as lymphomas, or from metastatic deposits seeded by distant epithelial tumours. Clinicians assess whether the enlargement is localised to a single nodal basin or generalised across multiple anatomical regions, alongside physical attributes such as firmness, tenderness, and immobility against adjacent structures.

Recognising and evaluating lymphadenopathy promptly ensures that serious conditions are diagnosed without unnecessary delay. The physical characteristics of an enlarged node offer immediate clinical guidance: soft, tender nodes typically suggest temporary infection, whereas hard, painless, or fixed nodes warrant immediate imaging and tissue biopsy. For patients already living with cancer, emerging lymphadenopathy can provide crucial evidence regarding treatment response, disease progression, or regional recurrence, prompting timely changes in therapeutic strategy.

Evaluation begins with physical palpation, followed by imaging assessments such as high-resolution ultrasound, CT scans, or whole-body PET-CT to examine internal nodal basins. If a malignancy is suspected, definitive diagnosis requires tissue sampling. This is achieved via fine-needle aspiration (FNA) cytology or, preferably, a core needle or excisional biopsy to preserve nodal architecture for histological, cytogenetic, and flow cytometric analyses.

Lymphadenopathy is the primary initial finding in haematological malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma, and various forms of lymphocytic leukaemia. It also manifests frequently across metastatic solid tumours. For example, painless enlargement of supraclavicular nodes may reflect spread from gastric, lung, or oesophageal cancers. Similarly, pelvic and retroperitoneal adenopathy often occurs in gynaecological, testicular, colorectal, and prostate malignancies.

Because lymphadenopathy is a clinical sign rather than a standalone disease, management is entirely determined by its root cause. If benign, reassurance and clinical surveillance suffice. If malignant, identifying the underlying histology directly shapes systemic interventions such as immunochemotherapy or targeted small-molecule inhibitors. Radiation fields or surgical plans may also be adapted to ensure involved regional nodal groups are adequately treated.